Related content

Tandem myeloablative ¹³¹I-rituximab radioimmunotherapy and high-dose chemotherapy in refractory/relapsed non-Hodgkin lymphoma patients

By Deshayes Emmanuel   Kraeber-Bodéré Françoise   Vuillez Jean-Philippe   Bardiès Manuel   Teulon Isabelle   Pouget Jean-Pierre  

Immunotherapy, Vol. 5, Iss. 12, 2013-12 ,pp. : 1283-1286

Future Medicine

Access to resources Recommend Favorite

Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin’s lymphoma: a single-centre study of 20 patients

By Aydin Semra   Dührsen Ulrich   Nückel Holger  

Annals of Hematology, Vol. 86, Iss. 4, 2007-04 ,pp. : 271-276

Springer Publishing Company

Access to resources Recommend Favorite

Rituximab added to an intensified salvage chemotherapy program followed by autologous stem cell transplantation improved the outcome in relapsed and refractory aggressive non-Hodgkin lymphoma

By Sieniawski Michal   Staak Oliver   Glossmann Jan-Peter   Reineke Thorsten   Scheuß Helena   Diehl Volker   Engert Andreas   Josting Andreas  

Annals of Hematology, Vol. 86, Iss. 2, 2007-02 ,pp. : 107-115

Springer Publishing Company

Access to resources Recommend Favorite

Rituximab used in three cases with relapsed nonHodgkin's lymphoma

By Elli  

Molecular and Clinical Oncology, Vol. 1, Iss. 3, 2013-01 ,pp. : 550-552

Spandidos Publications

Access to resources Recommend Favorite

Immunogenicity of Influenza Vaccination in Patients with Non-Hodgkin Lymphoma

By Centkowski Piotr   Brydak Lidia   MachaŁa Magdalena   Kalinka-Warzocha Ewa   BŁAsiŃSka-Morawiec Maria   Federowicz Irena   Walewski Jan   Wc{E}? Joanna   WoŁOwiec Dariusz   Lech-MaraŃDa Ewa   Sawczuk-Chabin Joanna   BiliŃSki PrzemysŁAw   Warzocha Krzysztof  

Journal of Clinical Immunology, Vol. 27, Iss. 3, 2007-05 ,pp. : 339-346

Springer Publishing Company

Access to resources Recommend Favorite